Back to MPT Database

TFV/EFV Nanoparticles-in-film

This product introduces a new vaginal delivery system comprising the incorporation of tenofovir (TFV) and efavirenz (EFV)-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs) into a polymeric film base (TFV/EFV NPs-in-film). TFV/EFV NPs-in-film was tested for its ability to deliver incorporated drugs. The delivery system provided enhanced genital distribution of drugs over 24 hours in mice, allowing higher genital concentrations of both drugs, namely as compared to their delivery in a liquid vehicle. Levels of EFV were also enhanced as compared to a film containing the drug directly dispersed in the film polymeric matrix. TFV/EFV NPs-in-film were further shown to be safe upon daily vaginal delivery for 14 -days to mice.

Development Stage:

Preclinical – Advanced (Pre2)



Delivery Route & Method:

Topical - Film - Vaginal

Mechanism of Action:

Short-term (on-demand) protective film that dissolves on contact with vaginal fluids to deliver combination antiviral compounds


  • Inst. for Research & Innovation in Health (i3S), U. of Porto


  • Foundation for Science and Technology, Portugal

Funding Mechanism:

Grant Project UID/BIM/04293/2019

Past Funding:

European Regional Development Fund (ERDF) through COMPETE 2020 Program;
Gilead Portugal

Active Ingredient(s):

  • Efavirenz (EFV)
  • Tenofovir (TFV)

Product Indication(s):

  • HIV
  • HSV-1
  • HSV-2

Back to MPT Database